The effects of topical moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution on corneal healing after bilateral photorefractive keratectomy

Cornea

Volumn 25, Issue 9 SUPPL. 2, 2006, Pages

  Yee, Richard W ^a   Setabutr, Pete ^a   Foltermann, Miles O ^a   Sami, Mirwat S ^a   Chuang, Alice Z ^a  

^a Hermann Eye Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GATIFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; CORNEA CELL; CORNEA EPITHELIUM; DRUG EFFECT; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; KERATITIS; MALE; PHOTOREFRACTIVE KERATECTOMY; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; SLIT LAMP; VISUAL ACUITY; WOUND HEALING;

EID: 33845415140     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ico.0000176607.17871.6e     Document Type: Article

References (14)

1. Vigamox® package insert. Fort Worth, TX: Alcon Laboratories, Inc.; 2003.
2. Zymar® package insert. Irvine, CA: Allergan Inc.; 2003.
3. Mather R, Karenchak LM, Romanowski EQ, et al. Fourth-generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol. 2002;133:463-466.
4. Katz H. Successful treatment of a Pseudomonas aeruginosa corneal ulcer in a human patient with moxifloxacin 0.5% (Vigamox). Presented at The European Society of Cataract and Refractive Surgery, Paris, France, June 2004.
5. Yee RW, Sorour HM, Yee SB, et al. Comparison of relative toxicity of four ophthalmic antibiotics using the human cornea epithelial cell culture system. Invest Ophthalmol Vis Sci. 2004;45(Suppl.):4939.
6. Fowler WC, Roberts BC, Zaravnaya E, et al. An animal model for LASIK flap research: The White Leghorn chicken. Invest Ophthalmol Vis Sci. 2000;41(Suppl.):459.
7. Fowler AM, Roberts BC, Fowler WC, et al. Corneal re-epithelialization rates following application of bandage contact lens and eyelid tarsorhaphy. Invest Ophthalmol Vis Sci. 2003;44(Suppl.):3819.
8. Kovoor TA, Kim AS, McCulley JP, et al. Evaluation of the corneal effects of topical ophthalmic fluoroquinolones using in vivo confocal microscopy. Eye Contact Lens. 2004;30:90-94.
9. Herrygers LA, Noecker RJ, Lane LC, et al. Comparison of corneal surface effects of gatifloxacin and moxifloxacin using intensive and prolonged dosing protocols. Cornea. 2005;24:66-71.
10. Owen GR, Dembinska O, Stout KR, et al. Corneal penetration and change in corneal permeability of moxifloxacin versus gatifloxacin. Invest Ophthalmol Vis Sci. 2004;45(Suppl.):4910.
11. Donaldson KE, Marangon FB, Schatz L, et al. Confocal analysis of the effects of moxifloxacin on the normal human cornea. Presented at The American Society of Cataract and Refractive Surgeons, San Diego, California, May 2004.
12. Nguyen QH, Friedlaender MH, Sharf L, et al. Objective and subjective measurement of drug toxicity. Invest Ophthalmol Vis Sci. 2004;45(Suppl.):4937.
13. Durrie DS, Trattler W. A comparison of therapeutic regimens containing moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% ophthalmic solution for surgical prophylaxis in patients undergoing LASIK or LASEK. J Ocular Pharm Ther. 2005;21:236-241.
14. Solomon R, Donnenfeld ED, Perry HD, et al. The effect of gatifloxacin 0.3% and moxifloxacin 0.5% on corneal epithelial wound healing following photorefractive keratectomy. Presented at The American Academy of Ophthalmology, New Orleans, LA, October 2004.